phentermine

(redirected from Qsymia)
Also found in: Dictionary.
Related to Qsymia: phentermine, Topiramate, Belviq

phentermine

 [fen´ter-mēn]
a sympathomimetic amine related to amphetamine, used as an appetite suppressant either as the hydrochloride salt or as the base in a complex with a resin, which has a sustained action.

phentermine

/phen·ter·mine/ (fen´ter-mēn) a sympathomimetic amine related to amphetamine, used as an anorectic either as the hydrochloride salt or as the base complexed with an ion exchange resin.

phentermine

(fĕn′tər-mēn′)
n.
A drug, C10H15N, that suppresses appetite by altering the metabolism of the neurotransmitter norepinephrine and is used in its hydrochloride form in the management of obesity.

phentermine

A drug with an AMPHETAMINE (amfetamine)-like action used for appetite control in obesity. A brand name is Duromine. There is evidence that phentermine may be associated with heart valve disease and pulmonary hypertension.

Phentermine

An amphetamine prescribed for appetite suppression.
Mentioned in: Weight Loss Drugs
References in periodicals archive ?
In phase III clinical trials of Qsymia, quite a few women got pregnant, which is not surprising, since women who are obese may have more difficulty knowing they are pregnant, for hormonal and other reasons.
If you are pregnant or plan to become pregnant, talk to your health care provider about using Qsymia or any medications.
Similarly, last year FDA said women who want to use a new weight-loss drug, Qsymia, need testing first to be sure they're not pregnant.
But Vivus, which sent out only 150 sales representatives to a target market of 25,000 doctors, is betting on slow, steady marketing of the Qsymia drug to win over customers.
ScinoPharm supplies 15 to 20-tons of slimming drug API per year for Qsymia, a new diet drug produced by Vivus, and the volume is expected to double by 2013.
has received Food and Drug Administration approval of Qsymia as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.
According to the BBC, the FDA approved the use of Qsymia for patients who are overweight or obese and have at least one other weight-related condition.
Utilizing its unique drug delivery capabilities, Catalent partnered with VIVUS during the development of Qsymia, including pre-formulation and formulation, clinical supply and validation.
Under the agreement, VIVUS will pay a one-time upfront fee plus royalty to Janssen on Qsymia product sales for these topiramate-related patents.